Lilly (LLY.US) partners with AdvanCell to jointly promote cancer alpha therapy.

Recently, American pharmaceutical giant Eli Lilly and Company (LLY.US) announced a partnership agreement with Australian biotechnology company AdvanCell to jointly develop Alpha Therapies for cancer treatment. AdvanCell is a biotechnology company focused on radioactive therapy, with its core technology being the Alpha Isotope Generator, which addresses the biggest issue in targeted alpha therapy: stable and scalable isotope supply. This breakthrough technology has the potential to provide more reliable treatment options for cancer patients. Under the agreement, AdvanCell will provide its Pb-212 (lead-212) production technology and radioactive isotope development infrastructure to combine with Lilly's drug pipeline and advance a series of targeted alpha therapy developments. Pb-212 is a radioactive isotope that can precisely target cancer cells, reducing damage to healthy tissues, and improving efficacy while reducing side effects. Currently, AdvanCell's most advanced candidate drug ADVC001 has entered Phase I/II clinical trials, primarily for treating prostate cancer. This partnership is expected to accelerate the development process of this therapy, bringing new hope for cancer patients.